ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -15.09% and +2.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?